Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity

Arthritis and Rheumatism

Volumn 50, Issue 11, 2004, Pages 3690-3697

  Manicourt, Daniel Henri ^a,b   Brasseur, Jean Pierre ^a   Boutsen, Yves ^a   Depreseux, Geneviève ^a   Devogelaer, Jean Pierre ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALCATONIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BONE REMODELING; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEARTBURN; HUMAN; JOINT MOBILITY; LEG; LEG EDEMA; LEG PAIN; MALE; NAUSEA; NOCICEPTION; OSTEOCLAST; OSTEOLYSIS; PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD; STATISTICAL ANALYSIS; TREATMENT OUTCOME; URINE LEVEL;

ADMINISTRATION, ORAL; ADULT; ALENDRONATE; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; MOVEMENT; PAIN; PALLIATIVE CARE; PEPTIDES; REFLEX SYMPATHETIC DYSTROPHY; TREATMENT OUTCOME;

EID: 8444227092     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20591     Document Type: Article

References (38)

1. Stanton-Hicks M, Janig W, Hassenbusch S, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain 1995;63:127-33.
2. Doury P. Algodystrophy: reflex sympathetic dystrophy syndrome. Clin Rheumatol 1988;7:173-80.
3. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet 1993;342:1012-6.
4. Bonica J. Causalgia and other reflex sympathetic dystrophies. In: Bonica J, editor. The management of pain. Philadelphia: Lea & Febiger; 1990. p. 220-43.
5. Kozin F. Reflex sympathetic dystrophy syndrome. Curr Opin Rheumatol 1994;6:210-6.
6. Schwartzman RJ, Popescu A. Reflex sympathetic dystrophy. Curr Rheumatol Rep 2002;4:165-9.
7. Janig W, Baron R. Complex regional pain syndrome: mystery explained? Lancet Neurol 2003;2:687-97.
8. Bickerstaff DR, Kanis JA. Algodystrophy: an under-recognized complication of minor trauma. Br J Rheumatol 1994;33:240-8.
9. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci 2001;2:83-91.
10. Schwartzman RJ, Grothusen J, Kiefer TR, Rohr P. Neuropathic central pain: epidemiology, etiology, and treatment options. Arch Neurol 2001;58:1547-50.
11. Bacorn RW, Kurtzke JF. Colles' fracture: a study of two thousand cases from the New York State Workmen's Compensation Board. J Bone Joint Surg Am 1953;35A:643-58.
12. Bengtson K. Physical modalities for complex regional pain syndrome. Hand Clin 1997;13:443-54.
13. Stanton-Hicks M, Baron R, Boas R, Gordh T, Harden N, Hendler N, et al. Complex regional pain syndromes: guidelines for therapy. Clin J Pain 1998;14:155-66.
14. Schott GD. Reflex sympathetic dystrophy. J Neurol Neurosurg Psychiatry 2001;71:291-5.
15. Forouzanfar T, Koke AJ, van Kleef M, Weber WE. Treatment of complex regional pain syndrome type I. Eur J Pain 2002;6:105-22.
16. Devogelaer JP, Dall'Armellina S, Huaux JP, Nagant de Deuxchaisnes C. Dramatic improvement of intractable reflex sympathetic dystrophy syndrome by intravenous infusions of the second generation bisphosphonate APD. J Bone Miner Res 1988;S3:122.
17. Adami S, Fossaluzza V, Gatti D, Fracassi E, Braga V. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997;56:201-4.
18. Varenna M, Zucchi F, Ghiringhelli D, Binelli L, Bevilacqua M, Bettica P, et al. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome: a randomized, double blind, placebo controlled study. J Rheumatol 2000;27:1477-83.
19. Maillefert JF, Cortet B, Aho S. Pooled results from 2 trials evaluating bisphosphonates in reflex sympathetic dystrophy [letter]. J Rheumatol 1999;26:1856-7.
20. Kubalek I, Fain O, Paries J, Kettaneh A, Thomas M. Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. Rheumatology (Oxford) 2001;40:1394-7.
21. Harden RN, Bruehl S, Galer BS, Saltz S, Bertram M, Backonja M, et al. Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive? Pain 1999;83:211-9.
22. Demangeat JL, Constantinesco A, Brunot B, Foucher G, Farcot JM. Three-phase bone scanning in reflex sympathetic dystrophy of the hand. J Nucl Med 1988;29:26-32.
23. Manicourt DH. L'exploration scintigraphique dans l'algodystrophie sympathique réflexe. Semin Hop Paris 1994;33-34: 1023-42.
24. Atkins RM, Kanis JA. The use of dolorimetry in the assessment of post-traumatic algodystrophy of the hand. Br J Rheumatol 1989; 28:404-9.
25. Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002;2:571-7.
26. Basle MF, Rebel A, Renier JC. Bone tissue in reflex sympathetic dystrophy syndrome-Sudeck's atrophy: structural and ultrastructural studies. Metab Bone Dis Relat Res 1983;4:305-11.
27. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
28. Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521-8.
29. Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD, Mach DB, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61:4038-47.
30. Wasner G, Schattschneider J, Binder A, Baron R. Complex regional pain syndrome - diagnostic, mechanisms, CNS involvement and therapy. Spinal Cord 2003;41:61-75.
31. Bonjour JP, Rizzoli R, Ammann P, Chevalley T. Bisphosphonates in clinical medicine. In: Heershe NM, Kanis JK, editors. Bone and mineral research. Amsterdam: Elsevier Science; 1994. p. 204-64.
32. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46: 766-73.
33. Bonabello A, Galmozzi MR, Canaparo R, Serpe L, Zara GP. Long-term analgesic effect of clodronate in rodents. Bone 2003; 33:567-74.
34. Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells in vitro. Pharm Res 1995;12:916-22.
35. Bishop NJ, Ninkovic M, Alexander GJ, Holmes SD, Milligan T, Price C, et al. Changes in calcium homoeostasis in patients undergoing liver transplantation: effects of a single infusion of pamidronate administered pre-operatively. Clin Sci (Lond) 1999; 97:157-63.
36. Carr DB, Goudas LC. Acute pain. Lancet 1999;353:2051-8.
37. Sluka KA. Blockade of calcium channels can prevent the onset of secondary hyperalgesia and allodynia induced by intradermal injection of capsaicin in rats. Pain 1997;71:157-64.
38. Liu T, van Rooijen N, Tracey DJ. Depletion of macrophages reduces axonal degeneration and hyperalgesia following nerve injury. Pain 2000;86:25-32.